Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03309943 · ClinicalTrials.gov registry record · Phase 4
Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT03309943 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 44 participants.
The verdict
NCT03309943, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
The central objective of this project is to obtain proof-of-concept data demonstrating the effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to personal smoking environments and behavioral responses in a laboratory smoking behavior task. Human cigarette smokers (N = 50) will take photographs of locations where they do and do not smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg) or placebo prior to completing: A) An MRI session assessing neural responses to personal smoking/non-smoking environments, standard smoking/non-smoking environments and proximal smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response to environmental cues.
Interventions
- DRUG Placebo
- DRUG Propranolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2019-07-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03309943
The ClinicalTrials.gov registry entry for NCT03309943 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03309943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03309943 about?
NCT03309943 is a clinical study titled "Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity". The central objective of this project is to obtain proof-of-concept data demonstrating the effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to personal smoking environments and behavioral responses in a laboratory smoking behavior task. Human cigarette smokers (N = ...
What is the current status of trial NCT03309943?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2018-01-16. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT03309943?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG).
Who is sponsoring clinical trial NCT03309943?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.